- Home
- WY vs JAZZ Comparison
WY vs JAZZ Comparison
Compare WY & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WY | JAZZ |
|---|---|---|
| Founded | 1900 | 2003 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.6B | 15.6B |
| IPO Year | 1994 | 2007 |
Fundamental Metrics
Financial Performance| Metric | WY | JAZZ |
|---|---|---|
| Price | $24.01 | $255.45 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 14 |
| Target Price | $28.86 | ★ $217.57 |
| AVG Volume (30 Days) | ★ 4.9M | 658.1K |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.46% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.22 | ★ 4.43 |
| Revenue | ★ $6,905,000,000.00 | $1,618,693,000.00 |
| Revenue This Year | $5.78 | $6.22 |
| Revenue Next Year | $8.94 | $7.68 |
| P/E Ratio | $108.68 | ★ $57.66 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.16 | $105.00 |
| 52 Week High | $27.75 | $257.00 |
Technical Indicators
Market Signals| Indicator | WY | JAZZ |
|---|---|---|
| Relative Strength Index (RSI) | 51.35 | 62.73 |
| Support Level | $23.67 | $222.49 |
| Resistance Level | $25.14 | N/A |
| Average True Range (ATR) | 0.57 | 7.11 |
| MACD | 0.04 | 0.79 |
| Stochastic Oscillator | 59.78 | 86.64 |
Price Performance
Historical ComparisonAbout WY Weyerhaeuser Company
Weyerhaeuser Co ranks among the world's key forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.